SANTA MONICA, Calif., Oct. 3, 2014 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Kite) (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, today announced that David Chang, M.D., Ph.D., Kite Pharma's Executive Vice President, Research and Development, and Chief Medical Officer, will participate in the "T-Cell Therapies: Best Bets in Pushing Down the Cost Curve and Prioritizing Cancer Targets" panel at the 13th Annual BIO Investor Forum on Tuesday, October 7, 2014, at 9:00 am PDT in San Francisco, CA.
About Kite Pharma, Inc.
Kite Pharma, Inc., is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a primary focus on eACT™ designed to restore the immune system's ability to recognize and eradicate tumors. In partnership with the NCI Surgery Branch through a Cooperative Research and Development Agreement (CRADA), Kite is advancing a pipeline of proprietary eACT™ product candidates, both CAR (chimeric antigen receptor) and TCR (T cell receptor) products, directed to a wide range of cancer indications. Kite is based in Santa Monica, CA. For more information on Kite Pharma, please visit www.kitepharma.com.
CONTACT: Kite PharmaCynthia M. Butitta
Chief Financial Officer and Chief Operating Officer
310-824-9999
For Media: Justin Jackson
For Investor Inquiries: Kimberly MinarovichBurns McClellan
212-213-0006
jjackson@burnsmc.comkminarovich@burnsmc.com
Source:
Kite Pharma, Inc.News Provided by Acquire Media
